Why did Zoetis cut its full-year 2026 guidance?

Management cited a more pressured Companion Animal market, with lower clinic visits, pet owner price sensitivity, and heightened competition in key categories. Revenue guidance moved from an organic growth range of 2% to 5% to a decline of (3)% to (1)%, and adjusted EPS guidance fell from $6.85-$7.00 to $6.15-$6.25.

How did the U.S. and International segments perform in the second quarter?

U.S. revenue fell 7% to $1.27 billion, driven by an 11% decline in Companion Animal, partly offset by a 23% rise in Livestock. International revenue rose 8% reported and 6% organically to $1.17 billion, led by parasiticides, Revolution, Stronghold, diagnostics, and the new Lenivia and Portela launches.

Did the share count change affect per-share results?

Yes. Diluted weighted-average shares fell to 417.7 million from 445.5 million, a decline of about 6%. This helped GAAP diluted EPS rise 1% to $1.65 even though net income fell 5% to $691 million, and it helped adjusted EPS grow 5% reported even as adjusted net income declined 1%.

What are the main drivers of the increase in restructuring and significant-item charges?

Certain significant items were $81 million pre-tax in Q2 2026 versus $48 million a year earlier, primarily from other restructuring charges tied to a comprehensive cost and productivity program. Management now expects total significant items and acquisition-related costs of about $150 million for the full year, up from about $100 million previously.

What growth catalysts did Zoetis highlight despite the weak quarter?

Zoetis pointed to a pipeline with more than 12 potential blockbusters, the Lenivia and Portela OA pain launches, FDA conditional approval of Dectomax-CA1 for New World screwworm, the European approval of Poulvac Procerta HVT-ND, and the VitalRADS teleradiology acquisition. Management said these support its long-term position, but the filing does not quantify their expected near-term revenue contribution.

ZTS 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed August 6, 2026. Cited figures are marked; the original filing is the authoritative source.

Zoetis reported second quarter 2026 results on August 6, 2026, with revenue flat year over year at $2.5 billion^a ($2,468 million) on a reported basis and down 1% on an organic operational basis.

GAAP net income was $691 million^b, or $1.65 per diluted share, down 5% in dollars but up 1% per share thanks to a lower share count (417.7 million diluted shares versus 445.5 million a year earlier). Adjusted net income was $781 million, or $1.87 per diluted share, down 2% organically. The quarter was dominated by weakness in the U.S. Companion Animal business, where revenue fell 11% on softer end-market demand, pricing pressure on the dermatology franchise and Simparica Trio, and generic competition for Cerenia and Convenia.

Livestock (up 23% in the U.S.) and International growth (up 6% organically) partly offset the decline. The more significant news for investors is the guidance cut. Full-year 2026 revenue guidance was lowered to $9.120^c-$9.320 billion, implying organic operational growth of (3)% to (1)%, down from the prior 2% to 5% range given in May.

Adjusted diluted EPS guidance was reduced to $6.15^d-$6.25 from $6.85-$7.00, and reported diluted EPS guidance to $5.55-$5.65 from $6.35-$6.50. Management attributed the revision to a more pressured Companion Animal market, including lower clinic visits, pet owner price sensitivity, and heightened competition. The company also flagged higher restructuring and cost-reduction charges, with certain significant items and acquisition-related costs now expected to total about $150 million, up from $100 million.

Management is responding with targeted commercial investments, accelerated innovation, and business development. The company highlighted new approvals and launches, including Lenivia and Portela (long-acting osteoarthritis pain antibodies), Dectomax-CA1 as the first FDA conditional approval for New World screwworm, and the VitalRADS teleradiology acquisition. Investors should weigh these pipeline and diversification efforts against near-term earnings pressure, the sharp guidance reduction, and the ongoing Companion Animal headwinds.

02—Key points

Key Highlights

Q2 2026 revenue was flat at $2,468 million (down 1% organically); U.S. revenue fell 7%, while International grew 6% organically.
U.S. Companion Animal sales fell 11% on softer demand, dermatology and Simparica Trio pricing pressure, and generic competition for Cerenia and Convenia.
Livestock was a bright spot, with U.S. Livestock up 23% on cattle and poultry strength, and global Livestock up 12% reported.
Full-year 2026 revenue guidance was cut to $9.120-$9.320 billion from $9.680-$9.960 billion, moving to an organic decline of (3)% to (1)%.
Adjusted diluted EPS guidance was lowered to $6.15-$6.25 from $6.85-$7.00, a reduction of roughly 10% at the midpoint.
GAAP diluted EPS was $1.65 (up 1%) and adjusted diluted EPS was $1.87 (up 5% reported, down 2% organic net income), helped by a 6% lower diluted share count year over year.
Restructuring and significant-item charges are expected to rise to about $150 million for 2026, reflecting a comprehensive cost and productivity program.

03—Questions

Frequently Asked Questions

Why did Zoetis cut its full-year 2026 guidance?
Management cited a more pressured Companion Animal market, with lower clinic visits, pet owner price sensitivity, and heightened competition in key categories. Revenue guidance moved from an organic growth range of 2% to 5% to a decline of (3)% to (1)%, and adjusted EPS guidance fell from $6.85-$7.00 to $6.15-$6.25.
How did the U.S. and International segments perform in the second quarter?
U.S. revenue fell 7% to $1.27 billion, driven by an 11% decline in Companion Animal, partly offset by a 23% rise in Livestock. International revenue rose 8% reported and 6% organically to $1.17 billion, led by parasiticides, Revolution, Stronghold, diagnostics, and the new Lenivia and Portela launches.
Did the share count change affect per-share results?
Yes. Diluted weighted-average shares fell to 417.7 million from 445.5 million, a decline of about 6%. This helped GAAP diluted EPS rise 1% to $1.65 even though net income fell 5% to $691 million, and it helped adjusted EPS grow 5% reported even as adjusted net income declined 1%.
What are the main drivers of the increase in restructuring and significant-item charges?
Certain significant items were $81 million pre-tax in Q2 2026 versus $48 million a year earlier, primarily from other restructuring charges tied to a comprehensive cost and productivity program. Management now expects total significant items and acquisition-related costs of about $150 million for the full year, up from about $100 million previously.
What growth catalysts did Zoetis highlight despite the weak quarter?
Zoetis pointed to a pipeline with more than 12 potential blockbusters, the Lenivia and Portela OA pain launches, FDA conditional approval of Dectomax-CA1 for New World screwworm, the European approval of Poulvac Procerta HVT-ND, and the VitalRADS teleradiology acquisition. Management said these support its long-term position, but the filing does not quantify their expected near-term revenue contribution.

04—Continue

← View all 8-K filings